Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma.

Autor: Verrienti A; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy. antonella.verrienti@uniroma1.it., Pecce V; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Grani G; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Del Gatto V; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Barp S; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Maranghi M; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Giacomelli L; Department of Surgical Sciences, Sapienza University of Rome, Rome, 00161, Italy., Di Gioia C; Department of Radiological, Oncological and Pathological Sciences, 'Sapienza' University of Rome, Rome, 00161, Italy., Biffoni M; Department of Surgical Sciences, Sapienza University of Rome, Rome, 00161, Italy., Filetti S; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Durante C; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy., Sponziello M; Department of Translational and Precision Medicine, Sapienza University of Rome, V.le del Policlinico 155, Rome, 00161, Italy.
Jazyk: angličtina
Zdroj: Journal of endocrinological investigation [J Endocrinol Invest] 2024 Sep 19. Date of Electronic Publication: 2024 Sep 19.
DOI: 10.1007/s40618-024-02467-3
Abstrakt: Purpose: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm, accounting for approximately 85% of all follicular cell-derived thyroid nodules. This study aimed to assess the diagnostic potential of circulating microRNA-146a-5p and microRNA-221-3p as biomarkers for PTC and their usefulness in monitoring disease progression during patient follow-up.
Methods: An observational study was conducted on two cohorts of PTC patients and healthy controls (HCs) using digital PCR. We collected patients' clinical, biochemical, and imaging data during the post-surgery surveillance. We analyzed the levels of circulating miRNAs in serum samples of patients before surgery and during the follow-up, including those with indeterminate/biochemical incomplete response (IndR/BIR) and residual thyroid tissues (Thy Residue).
Results: Both miR-146a-5p and miR-221-3p were confirmed as effective biomarkers for PTC diagnosis. They enabled differentiation between pre-surgery PTC patients and HCs with an area under the curve (AUC) of 92% and 87.3%, respectively, using a threshold level of 768,545 copies/uL for miR-146a-5p and 389,331 copies/uL for miR-221-3p. It was found that miRNA fold change levels, rather than absolute levels, can be useful during patient follow-up. In particular, we found that a fold change of 2 for miR-146a-5p and 2.2 for miR-221-3p can identify a progressive disease, regardless of the presence of TgAbs or remnant thyroid.
Conclusion: MiRNA-146a-5p and miRNA-221-3p, particularly the former, could be valuable diagnostic biomarkers for PTCs. They also seem to be effective in monitoring disease progression during patient follow-up by evaluating their fold change, even when thyroglobulin is uninformative.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: